

SCHEDULE III OF COMPANIES ACT, 2013

PART II - AUDITED STATEMENT OF PROFIT AND LOSS FOR THE FY 2016-17

Name of the Company - **PHARMAIDS PHARMACEUTICALS LIMITED**

Profit and Loss Statement for the year ended **31st March, 2017**

Particulars		Rs. in Lakhs				
		Quarter Ended			Year Ended	
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
		Audited	Unaudited	Audited	Audited	Audited
I Revenue From Operations		25.79	29.08	26.55	120.25	168.45
II Other Income		0.97	-	-	1.01	4.57
III Total Revenue (I+II)		26.76	29.08	26.55	121.26	173.02
IV Expenses						
Cost of Materials Consumed		(5.81)	1.33	-	-	-
Purchases of Stock-in-trade		20.69	19.16	25.66	64.49	114.51
Changes in inventories of finished goods Work-in-progress and Stock-in-trade		2.48	(6.75)	5.24	2.95	0.89
Employee benefits expense		1.91	3.26	3.70	16.63	20.30
Finance Costs		0.05	1.11	1.03	4.01	2.87
Depreciation and Amortisation expense		0.49	1.96	2.91	6.37	10.37
Admin and Other Manufacturing Expenses		41.84	11.19	8.01	70.53	67.29
Total Expenses		61.65	31.26	46.55	164.98	216.23
V Profit/ (Loss) before Exceptional and Extraordinary Items and tax (III-IV)		(34.89)	(2.18)	(20.00)	(43.72)	(43.21)
VI Exceptional Items		(51.97)	-	-	(51.97)	-
VII Profit/ (Loss) before Extraordinary Items and tax (V-VI)		17.08	(2.18)	(20.00)	8.25	(43.21)
VIII Extraordinary Items		-	-	-	-	-
IX Profit/ (Loss) before Tax (VII-VIII)		17.08	(2.18)	(20.00)	8.25	(43.21)
X Tax Expense:						
Current Tax Net		-	-	-	(2.72)	(3.45)
Deferred Tax		-	-	-	-	-
XI Profit/ (Loss) for the period from continuing operations (IX-X)		17.08	(2.18)	(20.00)	10.97	(39.76)
XII Profit/ (Loss) from discontinuing operations		-	-	-	-	-
XIII Tax Expense of discontinuing operations		-	-	-	-	-
XIV Profit/ (Loss) from discontinuing operations after tax (XII-XIII)		-	-	-	-	-
XV Profit/ (Loss) for the period (XI+XIV)		17.08	(2.18)	(20.00)	10.97	(39.76)
XVI Earnings Per Share (EPS)						
Basic		0.50	(0.06)	(0.59)	0.32	(1.17)
Diluted		0.50	(0.06)	(0.59)	0.32	(1.17)

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th May, 2017.
- The Audited Financial Results for the Quarter IV and Year ended 31st March, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013
- The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
- The figures of the current quarter ending on March 31, 2017 are the balancing figures between the audited figures of the full financial year ended March 31 st, 2017 and the published year to date figures upto third quarter ended December 31st, 2016
- Due to incurring heavy losses in the company and number of guidelines by drugs control Department for implementing WHO GMP guidelines in which company has to replace the entire plant with the latest machineries and equipment which was not practically possible for the company. Hence company has disposed of its assets to discharged company's liabilities and decided to diversify in trading activities for reviving the unit at appropriate time and location.

For PHARMAIDS PHARMACEUTICALS LIMITED

(Signature)
DR. GHISULAL JAIN
 MANAGING DIRECTOR

Place : Hyderabad
 Date : 30-05-2017



Pharmaids Pharmaceuticals Limited

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31.03.2017

(Rs. In Lakhs)

Particulars		As on 31.03.2017	As on 31.03.2016
		Audited	Audited
A	EQUITY AND LIABILITY		
1	SHARE HOLDERS' FUNDS:		
	(a) Share Capital	336.31	336.31
	(b) Reserves and Surplus	(193.53)	(204.50)
	Sub Total - Shareholders Fund	142.78	131.81
2	Share application money pending allotment	0.00	0.00
3	Minority Interest	0.00	0.00
4	Non-Current Liabilities		
	(a) Long term Borrowings	9.26	27.31
	(b) Deferred Tax (Net)	0.00	2.72
	(c) Other Long term Liabilities	0.00	0.00
	(d) Long Term Provisions	0.00	0.00
	Sub-Total - Non Current Liabilities	9.26	30.03
5	Current Liabilities		
	(a) Short Term Borrowings	2.65	20.52
	(b) Trade Payables	44.78	44.49
	(c) Other Current Liabilities	2.58	2.87
	(d) Short Term Provisions	0.00	0.00
	Sub-Total - Current Liabilities	50.01	67.88
	TOTAL EQUITY AND LIABILITY	202.05	229.72
B	Assets		
1	Non-Current Assets		
	(A) Fixed Asset	0.00	43.68
	(b) Non Current Investment	0.00	0.00
	(c) Deferred Tax Asset (Net)	0.00	0.00
	(d) Long term Loans and Advances	37.95	32.20
	(e) Other Non-Current Assets	0.00	0.01
	Sub-Total Non-Current Assets	37.95	75.89
2	Current Assets		
	(a) Current Investments	0.00	0.00
	(b) Inventories	24.46	28.80
	(c) Trade Receivables	78.77	107.42
	(d) Cash and Cash equivalents	60.87	17.61
	(e) Short Term Loans and Advances	0.00	0.00
	(f) Other Current Assets	0.00	0.00
	Sub-Total Current Assets	164.10	153.83
	TOTAL ASSETS	202.05	229.72





RAKESH S JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

B. Ramesh Kumar (Mob) : +91-9849025641

E-mail : rsjainassociates@rediffmail.com

14-6-191, Nagar Khana, Begum Bazar,
Hyderabad - 500 012. (T.S.) INDIA.

Date :

Auditor's Report On Quarterly Financial Results and Year to Date Results of M/s Pharmaids Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015

To
Board of Directors
M/s Pharmaids Pharmaceuticals Limited
Hyderabad

We have audited the quarterly financial results of **M/s Pharmaids Pharmaceuticals Limited** for the quarter ended **31st March 2017** and the year to date results for the period **01st April 2016 to 31st March 2017** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India , as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the loss and other financial information for the quarter ended 31st March, 2017 as well as the year to date results for the period from 01st April 2016 to 31st March 2017

For RAKESH S JAIN & ASSOCIATES
Chartered Accountants
Firm Registration no.:010129S



B. Ramesh Kumar
(B. Ramesh Kumar)
Partner
M.No: 200304

Place: Hyderabad
Date:30/05/2017